Ultrasound BI-RADS rates breast lesions consistently

Article

The Breast Imaging Reporting and Data System for ultrasound, developed by the American College of Radiology in 2003, can reliably characterize breast tumors, according to Duke University researchers.

The Breast Imaging Reporting and Data System for ultrasound, developed by the American College of Radiology in 2003, can reliably characterize breast tumors, according to Duke University researchers.

Dr. Andrea S. Hong and colleagues in the Duke radiology department appraised the BI-RADS nomenclature that describes tumors according to their shape, orientation, margins, and several ultrasound-specific features. They found that these ultrasound-based descriptors were significantly different in malignant and benign masses. The study had several limitations, but long-term outcomes from larger population and histology samples following current guidelines may yield more conclusive results.

"The ACR BI-RADS lexicon provides standardized terminology that facilitates accurate and consistent breast sonography and mammography reporting," the investigators wrote in the April issue of the American Journal of Roentgenology.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.